Sunday 18 October 2026
Export FULC’s income statement to Excel — free account
Fulcrum Therapeutics, Inc.
FULC Healthcare Biotechnology
Fulcrum Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $80.0 million, up 2,752.0% from fiscal 2023. In the quarter to June 2026, EPS fell 21.4% and free cash flow fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.65
0.02
−0.54%
Follow FULC
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(31.21%) | (25.30%) | (27.10%) | (32.38%) | |
| (28.80%) | (23.89%) | (25.83%) | (30.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(36.02%) | (21.56%) | (22.98%) | (27.20%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.97) | (0.96) | (0.84) | (0.86) | |
Free Cash Flow |
(60.43) | (60.61) | (63.88) | (65.69) | |
Capital Expenditures |
(0.40) | (0.54) | (0.32) | 0.09 | |
| Other line items | |||||
Cash ROIC |
(15.15%) | (8.64%) | (9.58%) | (10.43%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.84 | 0.80 | 0.84 | 0.77 | |
Depreciation/Fixed assets |
0.45 | 0.49 | 0.55 | 0.00 | |
Capex/Depreciation |
(0.29) | (0.39) | (0.23) | 0.07 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.96) | (0.95) | (0.83) | (0.86) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates